My Readers Are Making A Killing In Biotech… RIGHT NOW

You see, the geniuses behind GHLV aren’t a bunch of ivory tower eggheads holed-up in a lab somewhere, trying to win a Nobel Prize.

No, they’re a rare hybrid of “top-flight scientists and elite entrepreneurs”… and they’ve “cracked the code” for taking a company from zero to billions in value — for pennies on the dollar.

In short, they know how to make investors rich. Seriously rich.

What’s their secret?

Don’t Re-invent The Wheel… Make it Better

Their strategy is to take multi-billion dollar drugs — household names like Viagra — that are about to go off-patent, and give them a different and more effective delivery system (think under the tongue).

This allows GHLV to lower the dose, turn the drugs into an over-the-counter variety… and take over the market in the process.

In short, they’ve figured out how to leapfrog the competition and capture massive profits… in months, not decades.

As I write this, Global Health (GHLV) is developing three flagship products that tap into some of the largest and most lucrative markets in the world.

Let me describe them to you…

Target #1: Beat Viagra At Its Own Game

Their showcase product is targeting the erectile dysfunction market… a $3 billion industry that’s growing at an extraordinary pace, thanks to our aging population. And Global Health (GHLV) is developing a specially formulated drug that’s more effective — with fewer side effects — than Viagra itself.

The drug is called “X-Excite”. And it uses the same active ingredient as Viagra (sildenafil), so you know it’s going to work.

But instead of the pill being swallowed, Global Health (GHLV) is utilizing their proprietary sublingual delivery platform.  And this is where “X-Excite” gets really interesting…

Going sublingual provides three MAJOR advantages over Viagra.

	One, the effects of X-Excite kick-in SIX-TIMES faster than its blue-pilled cousin (approximately 5 minutes after intake vs 30 minutes for Viagra).
	Two, the drug has far fewer side effects. You see, because you’re not swallowing a pill, there’s no stomach or intestinal exposure. That means gastrointestinal side effects such as acidosis and diarrhea may well be completely eliminated.
	And three, because the dose is lower, the drug will be available at a lower cost.

All this adds up to a stunning triple-knockout:

more rapid onset of action, fewer side effects, and will be cheaper.

Target #2: The Obesity Epidemic

As everyone is now aware, an obesity epidemic is sweeping across North America.

In fact, the Centers for Disease Control and Prevention estimates it’s already begun to affect two-thirds of the U.S. population.

More startling however, is that the World Health Organization reports one out of six people worldwide are now affected by the medical problem.

That’s ONE BILLION PEOPLE.

Indeed, the market for anti-obesity products has enormous possibilities. Already the industry is raking-in an estimated $5 billion annually.

But the problem is, most of the people who go through intense forms of exercise and diet regain their weight within a few months of losing it.

It’s a vicious, unhealthy cycle that drives individuals mad.

And that’s where Global Health’s anti-obesity drug “T-Slim” comes in.

“T-Slim” is an appetite-suppressant with a simple but amazing twist that allows it to work on a cellular level. A brand new formulation, this drug utilizes a specialized, all-natural antioxidant called catechin to reduce appetite and, over time, manage weight loss through controlling food intake.

And unlike some of the more prominent forms of weight control available today, T-Slim is needle-free and will be available over-the-counter.

It doesn’t take a rocket scientist to figure out… this drug could rake-in billions over the coming years…
Making GHLV investors hugely rich in the process.

But that’s not all GHLV has up its sleeve.

The company has also identified another market that could blast your profits through the roof…  

Target #3: Cure Addiction

Global Health’s next game-changer is aptly named “Nico-Z”. That’s because “Nico-Z” is a sublingual formulation of nicotine designed to help smokers quit.

This multi-billion dollar industry has plenty of competition… but almost all currently marketed products (patches, gums or sprays) suffer from two major drawbacks: they’re either very poorly absorbed by the body thus limiting their effectiveness, or they’re inconvenient.

Nico-Z addresses both these issues by providing a super-high absorption efficiency AND being easy to use. Just pop Nico-Z under the tongue and almost instantly the drug hits the bloodstream.

Odds are, you or someone you know currently smokes, and would like to quit. In fact, it’s estimated that 60 million people in the US currently smoke.

And with more and more people trying to “kick the habit” everyday, this drug alone has the potential to propel the market-cap of GHLV through $500 million.

That translates into one thing for GHLV investors: “Cha-Ching.” The upside for Nico-Z is enormous.

Listen…

These industries are so enormous that if Global Health (GHLV) penetrates a mere fraction of just one percent, it will be enough to send its share price soaring.

And with drugs like “X-Excite” and “Nico-Z” — which are superior to products currently on the market — it’s easy to see this stock shooting through the stratosphere in the near-term.

That’s why GHLV is an immediate “must-buy”.
But you need to act quickly…

You see, the company is rapidly progressing along the path to commercialization (think months… not years), and if you don’t pick-up shares now — while they’re cheap — you will miss out. It’s no secret that a company with this much potential could easily…